Lidamitol tabs (Tablets) Instructions for Use
Marketing Authorization Holder
Grotex, LLC (Russia)
ATC Code
M03BX04 (Tolperisone)
Active Substance
Tolperisone (Rec.INN registered by WHO)
Dosage Form
| Lidamitol tabs | Film-coated tablets, 150 mg: 10, 20, or 30 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets
| Tolperisone | 150 mg |
10 pcs. – blister packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – blister packs (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – blister packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
Clinical-Pharmacological Group
Centrally acting muscle relaxant
Pharmacotherapeutic Group
Centrally acting muscle relaxants; other centrally acting muscle relaxants
Pharmacological Action
Centrally acting muscle relaxant. The reduction of pathologically increased skeletal muscle tone is explained by the ability of tolperisone to suppress spinal polysynaptic reflexes and its inhibitory effect on the caudal part of the reticular formation. It has central n-cholinoblocking properties. It does not have a significant effect on the peripheral parts of the nervous system. It has a weak antispasmodic and vasodilating effect.
Indications
Spinal and cerebral palsies (hypertonia, muscle spasm, spinal automatism; limb contracture).
Diseases accompanied by dystonia, rigidity, muscle spasm; obliterating arterial diseases: obliterating atherosclerosis of limb vessels, diabetic angiopathy, obliterating thromboangiitis (Buerger’s disease), Raynaud’s syndrome.
Consequences of disorders of vascular innervation (acrocyanosis, intermittent angioneurotic dysbasia).
Extrapyramidal disorders (postencephalitic and atherosclerotic parkinsonism).
Postthrombotic disorders of lymph circulation and venous circulation, trophic leg ulcer, infantile spastic paralysis (Little’s disease), epilepsy, encephalopathy of vascular origin; hypertonia combined with a violation of muscle tone of another type.
ICD codes
| ICD-10 code | Indication |
| G21.3 | Postencephalitic parkinsonism |
| G21.4 | Vascular parkinsonism |
| G24 | Dystonia (including dyskinesia) |
| G40 | Epilepsy |
| G80 | Cerebral palsy |
| G81.1 | Spastic hemiplegia |
| G82.1 | Spastic paraplegia |
| G82.4 | Spastic tetraplegia |
| G93.4 | Unspecified encephalopathy |
| I73.0 | Raynaud's syndrome |
| I73.1 | Obliterative thromboangiitis [Buerger's disease] |
| I73.8 | Other specified peripheral vascular diseases |
| I73.9 | Peripheral vascular disease, unspecified (including intermittent claudication, arterial spasm) |
| I79.2 | Peripheral angiopathy in diseases classified elsewhere (including diabetic angiopathy) |
| I87.0 | Postthrombotic syndrome |
| L98.4 | Chronic skin ulcer, not elsewhere classified |
| R25.2 | Cramp and spasm |
| ICD-11 code | Indication |
| 4A44.8 | Thromboangiitis obliterans |
| 7A82 | Sleep related leg cramps |
| 8A00.23 | Vascular parkinsonism |
| 8A00.2Y | Other specified secondary parkinsonism |
| 8A02.Z | Dystonic disorders, unspecified |
| 8A6Z | Epilepsy or epileptic seizures, unspecified |
| 8D2Z | Cerebral palsy, unspecified |
| 8E47 | Encephalopathy, not elsewhere classified |
| 8E4A.0 | Paraneoplastic or autoimmune disorders of the central nervous system, including brain and spinal cord |
| 8E63 | Post-cardiopulmonary bypass encephalopathy |
| BD42.0 | Raynaud's disease |
| BD42.1 | Raynaud's syndrome |
| BD42.Z | Raynaud's phenomenon, unspecified |
| BD4Z | Chronic obliterative arterial diseases, unspecified |
| BD53.Y | Other specified secondary involvement of arteries and arterioles |
| BD5Z | Diseases of arteries or arterioles, unspecified |
| BD74.Z | Chronic venous insufficiency of lower extremities, unspecified |
| EA40 | Tropical phagedenic ulcer |
| EF60 | Ischemic ulceration of the skin |
| EG00 | Dilation of skin vessels of the extremities |
| EM0Z | Unspecified skin disorder |
| MB40.7 | Acroparesthesia |
| MB47.3 | Convulsion or spasm |
| MB50.1 | Spastic tetraplegia |
| MB53.2 | Spastic hemiplegia |
| MB56 | Paraplegia |
| ME60.2 | Ulcerative skin lesion of unspecified nature |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer Lidamitol tablets orally with a full glass of water after a meal to minimize potential gastrointestinal discomfort.
Initiate therapy with an initial dose of 50 mg (one-third of a 150 mg tablet) taken two to three times daily.
Gradually titrate the dose upward based on individual patient tolerance and therapeutic response.
The standard maintenance dose for adults is 150 mg (one tablet) taken two to three times daily.
The maximum total daily dose should not exceed 450 mg, equivalent to three 150 mg tablets.
For intramuscular administration, inject 100 mg (1 ml of solution) twice daily deep into the muscle.
For intravenous administration, inject 100 mg (1 ml of solution) once daily as a single, slow injection.
Adhere strictly to the prescribed dosage and frequency; do not adjust the regimen without consulting a physician.
Discontinuation should be performed gradually under medical supervision if long-term therapy is concluded.
Adverse Reactions
Possible headache, myasthenia, arterial hypotension, nausea, vomiting, gastralgia, allergic reactions (anaphylactic shock, bronchospasm, urticaria, erythematous rash, skin itching).
Contraindications
Myasthenia, pregnancy, lactation period, children and adolescents under 18 years of age, hypersensitivity to tolperisone.
Use in Pregnancy and Lactation
Contraindicated during pregnancy and lactation.
Pediatric Use
Contraindicated in children under 1 year of age.
Special Precautions
Effect on ability to drive vehicles and mechanisms
Use with caution in patients whose activities require increased attention and speed of psychomotor reactions.
Drug Interactions
The effect of tolperisone is enhanced with simultaneous use with drugs for general anesthesia, peripheral muscle relaxants, psychoactive drugs, and with clonidine.
Storage Conditions
Store at 2°C (36°F) to 30°C (86°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer